Gorlin Syndrome, also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-–Goltz syndrome, is an infrequent multisystemic disease that is inherited in an autosomal dominant way and shows the high level of penetrance and variable expressiveness. Nevoid basal cell carcinoma syndrome (NBCCS) is known to be a rare autosomal dominantly inherited entity that is characterized most strikingly by the development of cutaneous basal cell carcinomas from an early age, typically puberty, although in some cases, it may occur earlier in childhood. Mutations in the PTCH1 gene cause Gorlin syndrome. This gene provides instructions for making a protein called patched-1, which functions as a receptor.
According to the National Institute of Health (NIH), individuals with Gorlin syndrome have a higher risk than the general population of developing other tumors. A small proportion of affected individuals develop a brain tumor called medulloblastoma during childhood. A type of benign tumor called a fibroma can occur in the heart or in a woman’s ovaries. Heart (cardiac) fibromas often do not cause any symptoms, but they may obstruct blood flow or cause irregular heartbeats (arrhythmia). However, ovarian fibromas, on the other hand, are not thought to affect a woman’s ability to have children (fertility).
DelveInsight’s “Gorlin Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Gorlin Syndrome, historical and forecasted epidemiology as well as the Gorlin Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Gorlin Syndrome market report also covers emerging drugs, current treatment practices, Gorlin Syndrome market size and share of the individual therapies, current and forecasted Gorlin Syndrome Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Gorlin Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Get FREE sample copy at:
Gorlin Syndrome Market Key Facts
- According to the National Institute of Health (NIH), United States, Gorlin syndrome affects an estimated 1 in 31,000 people. While more than 1 million new cases of basal cell carcinoma are diagnosed each year in the United States, less than 1% of these skin cancers are related to Gorlin syndrome.
- Cancer Research Organization (United Kingdom) suggests that Gorlin syndrome affects about 1 in 31,000 people. Between 70 and 80 out of every 100 people (70-80%) with Gorlin syndrome have someone else in their family with it, and have inherited a genetic mutation from one of their parents.
Key Benefits of Gorlin Syndrome Market Report
- Gorlin Syndrome market report provides an in-depth analysis of Gorlin Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
- The Gorlin Syndrome market report will help in developing business strategies by understanding the Gorlin Syndrome Market trends & developments, key players, and future market competition that will shape and drive the Gorlin Syndrome market in the upcoming years.
- The Gorlin Syndrome market report covers Gorlin Syndrome market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
- The report provides a detailed assessment of the Gorlin Syndrome patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Gorlin Syndrome market size is expected to increase during the forecast period owing to the launch of upcoming therapies.
Gorlin Syndrome Drugs Uptake and Key Market Players
The Gorlin Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gorlin Syndrome market or expected to get launched in the market during the study period. The analysis covers Gorlin Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Get FREE sample copy at:
Worldwide some of the major players are involved in developing therapies for the treatment and management of Gorlin Syndrome. The launch of emerging therapies is expected to fuels the growth of the market during the forecast period.
Gorlin Syndrome Companies:
And many others
Gorlin Syndrome Therapies covered in the report include:
And many more.
Get FREE sample copy at:
Table of Content
- Key Insights
- Executive Summary
- Gorlin Syndrome Competitive Intelligence Analysis
- Gorlin Syndrome Market Overview at a Glance
- Gorlin Syndrome Disease Background and Overview
- Gorlin Syndrome Patient Journey
- Gorlin Syndrome Epidemiology and Patient Population
- Gorlin Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
- Gorlin Syndrome Unmet Needs
- Key Endpoints of Gorlin Syndrome Treatment
- Gorlin Syndrome Marketed Products
- Gorlin Syndrome Emerging Therapies
- Gorlin Syndrome Seven Major Market Analysis
- Attribute Analysis
- Gorlin Syndrome Market Outlook (7 major markets)
- Gorlin Syndrome Access and Reimbursement Overview
- KOL Views on the Gorlin Syndrome Market.
- Gorlin Syndrome Market Drivers
- Gorlin Syndrome Market Barriers
- DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States